Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atreca, Inc.BCEL · Entity 91940 | Director | June 13, 2023 | June 15, 2023 |
| CERO THERAPEUTICS HOLDINGS, INC.CERO · Entity 8622 | Director | January 07, 2026 | January 09, 2026 |
| Clovis Oncology, Inc.CLVS · Entity 122635 | See Remarks | November 01, 2022 | November 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atreca, Inc.
Report date June 13, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2023-06-12 | Direct | 12,000 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control.
CERO THERAPEUTICS HOLDINGS, INC.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2036-01-06 | Direct | 690,900 |
Reported balance
After 2026-01-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 690,900 · Balance 690,900 |
Clovis Oncology, Inc.
Report date November 01, 2022 · Filed November 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 113,327 |
Reported balance
After 2022-11-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2022-11-01 · Exercise / conversion · Acquired 3,749 · Balance 113,327 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 111,419 |
Reported balance
After 2022-11-02 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2022-11-02 · Sale · Disposed 1,908 · Balance 111,419 F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Direct | 116,044 |
Reported balance
After 2022-11-01 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2022-11-01 · Exercise / conversion · Acquired 4,625 · Balance 116,044 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 113,691 |
Reported balance
After 2022-11-02 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2022-11-02 · Sale · Disposed 2,353 · Balance 113,691 F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,750 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Exercise / conversion · Disposed 3,749 · Balance 3,750 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,125 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Exercise / conversion · Disposed 4,625 · Balance 23,125 F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3: This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F5: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 3, 2021 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042707 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,625 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042707 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,747 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042707 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042707 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 347 | $4.89 | $1,696.83 |
DisclosureSEC source: 0000899243-21-035113 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,122 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.88 to $4.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-035113 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375 Underlying: Common Stock · 688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.exercise_date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-035113 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 21:32 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,317 | $4.82 | $11,167.94 |
DisclosureSEC source: 0000899243-21-031440 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,781 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.82 to $4.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 21:32 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,878 | $4.82 | $9,051.96 |
DisclosureSEC source: 0000899243-21-031440 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,473 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.82 to $4.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:32 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031440 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:32 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031440 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,496 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: This transaction was executed in multiple trades at prices ranging from $4.82 to $4.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:32 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031440 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| August 01, 2021 Filed Aug 3, 2021 21:32 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031440 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 16:31 UTC | Atreca, Inc. BCEL · Entity 91940 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $10.27 | $0.00 |
DisclosureSEC source: 0001209191-21-039839 · doc4.xml · derivative · entry 1 Rolfe Lindsey · CIK 0001650504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The option vests upon the earlier of the one-year anniversary of the date of grant or the day prior to the next Annual Meeting of Stockholders occurring after the grant date, subject to the non-employee director's continuous service on each applicable vesting date. All unvested options will vest in full immediately prior to a change in control (as defined in the Company's 2019 Equity Incentive Plan), subject to the non-employee director's continuous service as of immediately prior to the closing of such change in control. Read SEC document |
| June 03, 2021 Filed Jun 3, 2021 19:00 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 322 | $5.63 | $1,812.86 |
DisclosureSEC source: 0000899243-21-021857 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,602 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 19:00 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 687 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021857 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,063 Underlying: Common Stock · 687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · derivative.exercise_date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On March 1, 2018, the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 19:00 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021857 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| May 04, 2021 Filed May 4, 2021 21:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,486 | $5.54 | $13,772.44 |
DisclosureSEC source: 0000899243-21-018276 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,237 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $5.53 to $5.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 04, 2021 Filed May 4, 2021 21:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 2,015 | $5.54 | $11,163.10 |
DisclosureSEC source: 0000899243-21-018276 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,098 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $5.53 to $5.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018276 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,875 Underlying: Common Stock · 4,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018276 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,245 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 4,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018276 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| May 01, 2021 Filed May 4, 2021 21:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-018276 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 346 | $6.29 | $2,176.34 |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,364 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 315 | $6.29 | $1,981.35 |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,022 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · derivative · entry 7 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · derivative.exercise_date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · derivative.exercise_date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantRestricted Stock Units · Derivative | 81,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: Common Stock · 81,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units shall vest as to 25% of the units on March 1, 2022, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: The Restricted Stock Units shall vest as to 25% of the units on March 1, 2022, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-009493 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 9,822 | $7.97 | $78,281.34 |
DisclosureSEC source: 0000899243-21-004675 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,712 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $7.97 to $8.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2021 Filed Feb 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,991 | $7.97 | $15,868.27 |
DisclosureSEC source: 0000899243-21-004675 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,034 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $7.97 to $8.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004675 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,500 Underlying: Common Stock · 18,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F5 · date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.exercise_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F5 · derivative.expiration_date: On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004675 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,994 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 18,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-004675 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-004675 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 16:52 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034998 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.exercise_date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On December 19, 2016, the reporting person was granted 55,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on December 19, 2017, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 16:52 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,728 | $5.68 | $9,815.04 |
DisclosureSEC source: 0000899243-20-034998 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,275 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 16:52 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 3,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-034998 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 17,241 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0000899243-20-034109 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,241 shares Expires 2021-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the shares on March 1, 2012, and the remainder vested in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Tax withholdingCommon Stock | 14,153 | $5.11 | $72,321.83 |
DisclosureSEC source: 0000899243-20-034109 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,565 Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 17,241 | $3.28 | $56,550.48 |
DisclosureSEC source: 0000899243-20-034109 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 687 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032938 · doc4.xml · derivative · entry 6 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,438 Underlying: Common Stock · 687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F4 · date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.exercise_date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F4 · derivative.expiration_date: On March 1, 2018 , the reporting person was granted 11,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 625 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-032938 · doc4.xml · derivative · entry 5 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.exercise_date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On March 27, 2017, the reporting person was granted 10,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 346 | $4.89 | $1,691.94 |
DisclosureSEC source: 0000899243-20-032938 · doc4.xml · nonDerivative · entry 4 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,477 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032938 · doc4.xml · nonDerivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 315 | $4.89 | $1,540.35 |
DisclosureSEC source: 0000899243-20-032938 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,136 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionCommon Stock | 625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-032938 · doc4.xml · nonDerivative · entry 1 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | Exercise / conversionRestricted Stock Units · Derivative | 3,749 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-030475 · doc4.xml · derivative · entry 3 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,744 Underlying: Common Stock · 3,749 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one share of Common Stock. F3 · date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.exercise_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. F3 · derivative.expiration_date: On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 16:18 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | SaleCommon Stock | 1,920 | $4.93 | $9,465.60 |
DisclosureSEC source: 0000899243-20-030475 · doc4.xml · nonDerivative · entry 2 Rolfe Lindsey · CIK 0001650504 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,826 F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.